Fig. 4: HDGF is associated with gefitinib efficacy in NSCLC in vivo. | Cell Death Discovery

Fig. 4: HDGF is associated with gefitinib efficacy in NSCLC in vivo.

From: HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer

Fig. 4

NSCLC cells were subcutaneously inoculated in nude mice, which were then administered gefitinib for the indicated consecutive days after tumor formation. Tumor volume, representative images of tumors, and tumor weight of HDGF-knockdown H1975 xenografts treated with 50 mg/kg gefitinib (A–C) or HDGF-overexpressing PC-9 xenografts treated with 10 mg/kg gefitinib (D–F). G HDGF and Ki-67 expression levels in H1975 and PC-9 tumor tissues (20×). H, I Plasma HDGF concentrations in H1975 and PC-9 xenografts. J, K Plasma HDGF concentrations in NSCLC patients before receiving gefitinib or AZD9291 (a third-generation TKI) and after drug resistance occurred. L, M Plasma HDGF levels in each patient before and after receiving gefitinib or AZD9291. N HDGF expression in biopsy tissue samples measured by IHC before TKI treatment and after disease progression. Patient #1 received icotinib treatment and patient #2 administered AZD9291. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.

Back to article page